Filtering by Tag: cancer
Proteus Digital Health has launched an oral chemotherapy equipped with its ingestible sensor. The digital pill will be used to treat stage 3 and 4 colorecal cancer patients with capecitabine, and provide feedback to physicians by reporting the time, dose, and type of chemotherapy taken. This gives physicians a better opportunity to intervene if patients are not taking their medication correctly or miss a dose.
CellMax Life’s CMx platform filters out and counts precancer and cancer cells in the bloodstream. It’s FirstSightCRC test was able to detect the small, precancerous colon polyps known as adenomas with close to 90% accuracy. The increases in cell counts also correlates with increases in disease severity. This is a highly sensitive noninvasive testing option for precancer instead of a colonoscopy.
University of Queensland researchers developed a screening tool to inform clinicians if a patient may have cancer through a simple and inexpensive blood test. However, the procedure does not show where the cancerous cells are located and how serious the patient’s condition is. The test uses gold nanoparticles to detect for cancer DNA and the result is a colour change visible to the naked eye.
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
A new study from The Ohio State University found that mailing at-home HPV tests to hard-to-reach women may be a viable approach, one that could be especially helpful in regions such as Appalachia, where access to women’s health care can be limited.
The study, which appears in the journal Sexually Transmitted Diseases, found that almost 80 percent of women who received the kits used them and sent them back to the researchers for testing. About a quarter of them tested positive for a cancer-causing type of HPV.
Quanterix is expanding its blood biomarker testing business into oncology, providing an early access program to its benchtop imager and a new 10-plex assay panel for cancer research and drug development. The product covers more than 50 analytes and allows researchers to develop custom assays, including pharmacokinetic, pharmacodynamic and immunogenicity assays. The benchtop instrument includes a touchscreen interface and high-resolution camera, and requires little maintenance and calibration.
Biodesix has acquired Integrated Diagnostics and its precommercial XL2 lung cancer blood test. The test aims to help physicians rule out the patients that do not need to have a biopsy of a suspicious lung nodule by differentiating benign lung nodules from malignant ones using proteins found in the bloodstream.
A DNA-based blood panel developed by Exact Sciences and the Mayo Clinic accurately detected liver cancer across all stages of the disease and outperformed the most commonly used serum test in a phase 2 clinical validation study.
The assay tracks six methylated DNA markers found in blood plasma to detect hepatocellular carcinoma with 95% overall sensitivity.
Exact Sciences and the Mayo Clinic hope to further optimize the panel and plasma collection conditions prior to a phase 3 study.
Owlstone Medical has raised US$15 million to bring its breath-based cancer test to market. Through the analysis of exhaled volatile organic compounds (VOCs), the test will enable the detection of cancers and stratification of patients.
The primary completion of Owlstone’s lung cancer study is scheduled for next year. Success in the first study will position the company to bring its test to market and validate the concept. Owlstone plans to build on that validation by developing the diagnostic as a pan-cancer test and branching out into infectious and inflammatory diseases.
A blood test developed by VolitionRx has detected 80% of stage 1 colorectal cancers in a screening study. Its test is still being improved and its reliance on blood samples, rather than stool samples, potentially gives it an edge in colorectal cancer screening.
“Our tests use only a small amount of blood and could be added to routine blood screening regimens at a reasonable cost,” VolitionRx CEO Cameron Reynolds said in a statement. “We believe that with further development, our Nu.Q panel could form the basis of new [colorectal cancer] tests with early stage disease detection, and that our tests could become accessible to and usable by a wide section of the screening population around the world.”
Researchers at John Hopkins University developed a non-invasive blood test that can detect signs of eight different types of cancer in asymptomatic patients: ovary, liver, stomach, pancreas, esophagus, colon, lung and breast. Five of these cancers do not currently have screening tests. In addition, CancerSEEK can direct physicians toward the cancer’s location in a patient’s body.
The test looks for 16 genetic mutations in bits of free-floating DNA that have been deposited in the bloodstream by cancerous cells and 8 proteins that are usually found in higher quantities in the blood samples of people who have cancer.
Researchers estimate the cost of this single test will be less than US$500.